6
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      CYP2C8 but not CYP3A4 is important in the pharmacokinetics of montelukast.

      1 , ,
      British journal of clinical pharmacology
      Wiley

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          According to product information, montelukast is extensively metabolized by CYP3A4 and CYP2C9. However, CYP2C8 was also recently found to be involved. Our aim was to study the effects of selective CYP2C8 and CYP3A4 inhibitors on the pharmacokinetics of montelukast.

          Related collections

          Author and article information

          Journal
          Br J Clin Pharmacol
          British journal of clinical pharmacology
          Wiley
          1365-2125
          0306-5251
          Feb 2012
          : 73
          : 2
          Affiliations
          [1 ] Department of Clinical Pharmacology, University of Helsinki and HUSLAB, Helsinki University Central Hospital, P.O. Box 705, FI-00029 HUS, Finland.
          Article
          10.1111/j.1365-2125.2011.04086.x
          3269585
          21838784
          056c76c9-cc90-40d9-99a0-30496819071d
          History

          Comments

          Comment on this article